- Home
- QBTS vs IPHA Comparison
QBTS vs IPHA Comparison
Compare QBTS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QBTS
- IPHA
- Stock Information
- Founded
- QBTS 1999
- IPHA 1999
- Country
- QBTS United States
- IPHA France
- Employees
- QBTS N/A
- IPHA N/A
- Industry
- QBTS Retail: Computer Software & Peripheral Equipment
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- QBTS Technology
- IPHA Health Care
- Exchange
- QBTS Nasdaq
- IPHA Nasdaq
- Market Cap
- QBTS 5.9B
- IPHA 160.1M
- IPO Year
- QBTS N/A
- IPHA 2019
- Fundamental
- Price
- QBTS $18.35
- IPHA $2.08
- Analyst Decision
- QBTS Strong Buy
- IPHA Strong Buy
- Analyst Count
- QBTS 10
- IPHA 1
- Target Price
- QBTS $19.40
- IPHA $11.00
- AVG Volume (30 Days)
- QBTS 31.4M
- IPHA 10.2K
- Earning Date
- QBTS 11-13-2025
- IPHA 09-17-2025
- Dividend Yield
- QBTS N/A
- IPHA N/A
- EPS Growth
- QBTS N/A
- IPHA N/A
- EPS
- QBTS N/A
- IPHA N/A
- Revenue
- QBTS $22,275,000.00
- IPHA $20,831,349.00
- Revenue This Year
- QBTS $182.64
- IPHA $350.96
- Revenue Next Year
- QBTS $52.50
- IPHA $32.92
- P/E Ratio
- QBTS N/A
- IPHA N/A
- Revenue Growth
- QBTS 120.20
- IPHA N/A
- 52 Week Low
- QBTS $0.87
- IPHA $1.29
- 52 Week High
- QBTS $20.56
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- QBTS 64.56
- IPHA 49.16
- Support Level
- QBTS $14.88
- IPHA $1.93
- Resistance Level
- QBTS $15.96
- IPHA $2.06
- Average True Range (ATR)
- QBTS 0.88
- IPHA 0.10
- MACD
- QBTS 0.33
- IPHA -0.01
- Stochastic Oscillator
- QBTS 93.95
- IPHA 51.51
About QBTS D-Wave Quantum Inc.
D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.